Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Total Non-Current Liabilities (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $30.1 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 29.04% to $30.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.1 million through Dec 2025, down 29.04% year-over-year, with the annual reading at $30.1 million for FY2025, 29.04% down from the prior year.
  • Total Non-Current Liabilities hit $30.1 million in Q4 2025 for Bolt Biotherapeutics, down from $32.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $58.4 million in Q3 2021 to a low of $21.1 million in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $44.7 million across 5 years, with a median of $47.0 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 157.24% in 2022 and later dropped 29.04% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $57.4 million in 2021, then fell by 1.97% to $56.3 million in 2022, then dropped by 16.46% to $47.0 million in 2023, then decreased by 9.71% to $42.4 million in 2024, then decreased by 29.04% to $30.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BOLT at $30.1 million in Q4 2025, $32.8 million in Q3 2025, and $36.5 million in Q2 2025.